Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM. Hamadani M, et al. Among authors: farag ss. Biol Blood Marrow Transplant. 2008 Jul;14(7):783-9. doi: 10.1016/j.bbmt.2008.04.006. Biol Blood Marrow Transplant. 2008. PMID: 18541197 Free PMC article. Clinical Trial.
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. Blum W, et al. Among authors: farag ss. Biol Blood Marrow Transplant. 2006 Jan;12(1):61-7. doi: 10.1016/j.bbmt.2005.06.004. Biol Blood Marrow Transplant. 2006. PMID: 16399569 Free article.
Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.
Poi MJ, Hofmeister CC, Johnston JS, Edwards RB, Jansak BS, Lucas DM, Farag SS, Dalton JT, Devine SM, Grever MR, Phelps MA. Poi MJ, et al. Among authors: farag ss. Clin Pharmacokinet. 2013 Aug;52(8):705-12. doi: 10.1007/s40262-013-0064-7. Clin Pharmacokinet. 2013. PMID: 23588536 Free PMC article. Clinical Trial.
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Farag SS, Bolwell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum W, Sobecks R, Avalos BR, Byrd JC, Copelan E. Farag SS, et al. Bone Marrow Transplant. 2005 Apr;35(7):653-61. doi: 10.1038/sj.bmt.1704867. Bone Marrow Transplant. 2005. PMID: 15711571 Clinical Trial.
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).
Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C. Bashey A, et al. Biol Blood Marrow Transplant. 2011 Apr;17(4):558-65. doi: 10.1016/j.bbmt.2010.07.015. Epub 2010 Jul 30. Biol Blood Marrow Transplant. 2011. PMID: 20674758 Free PMC article. Clinical Trial.
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS. Benson DM Jr, et al. Among authors: farag ss. Blood. 2011 Dec 8;118(24):6387-91. doi: 10.1182/blood-2011-06-360255. Epub 2011 Oct 26. Blood. 2011. PMID: 22031859 Free PMC article.
95 results